The US Patent and Trademark Office took the unusual step of voicing concerns about the misuse of patent laws in a petition seeking a panel rehearing of a decision by the US Court of Appeals for the Federal Circuit. The commentary reflects the desire of the Biden Administration and members of Congress for the agency to consider the impact of patent practices on access to affordable drugs.
The Federal Circuit vacated a district court ruling that ImmunoGen, Inc.’s patent claims on a method of dosing its...